February 25, 2019
Marker Therapeutics announces updated data from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies.
February 15, 2019
Marker Therapeutics has formally relocated their corporate headquarters from Jacksonville, Florida to Houston, Texas. In addition, the Company has announced that it is now a resident company at Johnson & Johnson Innovation – JLABS (JLABS at TMC).
January 15, 2019
Data from four abstracts—including three oral presentations—were accepted for presentation at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research 2019.
May 16, 2018
It is great to welcome renowned thought leaders Dr. Cliona M. Rooney, Dr. Helen Heslop, current president of the American Society for Gene and Cell Therapy, and former President of ASGCT, Dr. Malcolm Brenner to the Scientific Advisory Board that will become effective in conjunction with the proposed merger between TapImmune and Marker Therapeutics, Inc.